CLINICAL_TRIALS
research
· 2015-05-05
Clinical Trial Update: ESHAP-Imatinib for Refractory/Relapsed Non-Hodgkin's Lymphoma [Phase 1, Phase 2]
Summary
A Phase 1/2 trial of ESHAP-Imatinib for refractory/relapsed Non-Hodgkin lymphoma is underway. The current status is unknown.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pusan National University Hospital | Conditions: Lymphoma, Non-Hodgkin | Phase 1, Phase 2 | Status: UNKNOWN